Literature DB >> 7987733

Androgen resistance and deficiency have different effects on the growing skeleton of the rat.

D Vanderschueren1, E Van Herck, P Geusens, A Suiker, W Visser, K Chung, R Bouillon.   

Abstract

Mature male, female, and androgen-resistant testicular feminized (Tfm) male rats of the same strain were sacrificed at the age of 120 days. Young male and Tfm rats were orchidectomized (orch) at 1 month of age and sacrificed at 120 days. The right femora were dissected, cleaned, defatted, and scanned with the Hologic QDR-1000. Orch and Tfm rats had similar body weights that were intermediate between body weights of their normal male and female littermates. Serum IGF-I concentrations were lowest in Tfm rats; IGF-1 concentrations in orch rats were not lower than in males. Dual-energy X-ray absorptiometry yielded the following results: Total femoral mass and area were lower in female, Tfm rats and in both orch groups compared with intact male rats. Femoral bone density was, however, only decreased in orch rats. Bone density measured in an area containing only cortical bone was not different between groups. However, the density was lower in orch rats in an area containing both cancellous and cortical bone. This finding is consistent with a +/- 50% decrease of cancellous bone volume in orch rats compared with all other groups at the proximal tibial metaphysis (an area containing mainly cancellous bone). These data show that Tfm rats, despite having lower IGF-I levels in serum, low body weight, and decreased femoral areas, manage--in contrast with orchidectomized rats--to maintain similar trabecular bone densities and volumes during growth. We conclude that trabecular bone densities can be preserved in androgen-resistant male rats independent of bone or body growth velocity or IGF-I secretion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987733     DOI: 10.1007/BF00425875

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  39 in total

1.  Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency.

Authors:  D Vanderschueren; E Van Herck; A M Suiker; W J Visser; L P Schot; R Bouillon
Journal:  Endocrinology       Date:  1992-05       Impact factor: 4.736

2.  Identification of androgen receptors in normal human osteoblast-like cells.

Authors:  D S Colvard; E F Eriksen; P E Keeting; E M Wilson; D B Lubahn; F S French; B L Riggs; T C Spelsberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

3.  Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy x-ray absorptiometry.

Authors:  P Ammann; R Rizzoli; D Slosman; J P Bonjour
Journal:  J Bone Miner Res       Date:  1992-03       Impact factor: 6.741

4.  Changes in skeletal mass and fragility with castration in the rat; a model of osteoporosis.

Authors:  P D Saville
Journal:  J Am Geriatr Soc       Date:  1969-02       Impact factor: 5.562

Review 5.  Sexual dimorphism in the control of growth hormone secretion.

Authors:  J O Jansson; S Edén; O Isaksson
Journal:  Endocr Rev       Date:  1985       Impact factor: 19.871

6.  Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation.

Authors:  R M Francis; M Peacock; J E Aaron; P L Selby; G A Taylor; J Thompson; D H Marshall; A Horsman
Journal:  Bone       Date:  1986       Impact factor: 4.398

7.  Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty.

Authors:  B S Keenan; G E Richards; S W Ponder; J S Dallas; M Nagamani; E R Smith
Journal:  J Clin Endocrinol Metab       Date:  1993-04       Impact factor: 5.958

8.  Growth and bone haemodynamic responses to castration in male rats. Reversibility by testosterone.

Authors:  A Schoutens; M Verhas; M L'Hermite-Baleriaux; M L'Hermite; A Verschaeren; N Dourov; M Mone; A Heilporn; A Tricot
Journal:  Acta Endocrinol (Copenh)       Date:  1984-11

9.  Testosterone metabolism in human bone.

Authors:  H U Schweikert; W Rulf; N Niederle; H E Schäfer; E Keck; F Krück
Journal:  Acta Endocrinol (Copenh)       Date:  1980-10

10.  Bone mineral homeostasis in spontaneously diabetic BB rats. II. Impaired bone turnover and decreased osteocalcin synthesis.

Authors:  J Verhaeghe; A M Suiker; B L Nyomba; W J Visser; T A Einhorn; J Dequeker; R Bouillon
Journal:  Endocrinology       Date:  1989-02       Impact factor: 4.736

View more
  7 in total

1.  Aromatization of androgens is important for skeletal maintenance of aged male rats.

Authors:  D Vanderschueren; E Van Herck; R De Coster; R Bouillon
Journal:  Calcif Tissue Int       Date:  1996-09       Impact factor: 4.333

Review 2.  Androgens and bone.

Authors:  D Vanderschueren; R Bouillon
Journal:  Calcif Tissue Int       Date:  1995-05       Impact factor: 4.333

Review 3.  Direct transcriptional targets of sex steroid hormones in bone.

Authors:  Susan A Krum
Journal:  J Cell Biochem       Date:  2011-02       Impact factor: 4.429

Review 4.  Unresolved issues in osteoporosis in men.

Authors:  E Seeman
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 5.  Recent experimental and clinical findings in the skeleton associated with loss of estrogen hormone or estrogen receptor activity.

Authors:  Eric P Smith; Bonny Specker; Kenneth S Korach
Journal:  J Steroid Biochem Mol Biol       Date:  2009-11-10       Impact factor: 4.292

6.  Bone mass in androgen-insensitivity syndrome: response to hormonal replacement therapy.

Authors:  M Muñoz-Torres; E Jódar; M Quesada; F Escobar-Jiménez
Journal:  Calcif Tissue Int       Date:  1995-08       Impact factor: 4.333

Review 7.  Sex hormones, their receptors and bone health.

Authors:  K Venken; F Callewaert; S Boonen; D Vanderschueren
Journal:  Osteoporos Int       Date:  2008-04-05       Impact factor: 4.507

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.